Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 Million

Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (‘Iovance’), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)). Terms of the agreement include an upfront payment of £166.7 [...]